Pathnostics products

Use molecular technology to differentiate the virus that causes COVID-19 from Flu and other respiratory viruses. Like other common respiratory tract infections, Influenza and SARS-CoV-2, the virus that causes COVID-19, share similar signs and symptoms. Additionally, co-infection with SARS-CoV-2 and other respiratory viruses, including influenza and RSV, has been described. It is estimated that SARS-CoV-2 co-infections may occur in 20.7% of patients.

This test identifies genetic abnormalities in patients with Barrett’s esophagus and provides an indication of progression requiring additional procedures and targeted management. Utilizing cytology, immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) testing on brushings from patients with Barrett’s esophagus, patient chromosomal alterations can be distinguished with high sensitivity and specificity with regard to level of dysplasia and adenocarcinoma.

The Pap smear is a screening procedure to aid in the detection of cancer and its precursors and should not be used as the sole means to detect cervical cancer. The FDA-approved Aptima® HPV assay is an in vitronucleic acid amplification test that detects several high-risk HPV types. The FDA-approved Aptima Combo 2® assay detects the presence of Chlamydia trachomatis and Neisseria gonorrhoeae.

The Gyn Cytology High Risk (HR) test is a powerful tool for stratifying borderline Pap test results, allowing physicians to identify the 10% of patients with borderline abnormal cells. This test can help physicians determine who will progress to cervical cancer and who will not.

The Pathnostics COVID-19 PCR Test detects the presence of SARS-CoV-2, the virus that causes COVID-19. The Pathnostics COVID-19 PCR Test is not impacted by the emerging B.1.1.529 (Omicron variant), enabling accurate test results.